Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...

Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

Havas Health Network is launching its groundbreaking GLP-1 consultancy in Europe with flagship event, "Shape Shifting: A ...

Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative ...

People on Ozempic and other GLP-1 agonist drugs commonly report they no longer have constant, incessant thoughts about food.

GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study sugges ...

Novo Nordisk (NVO) plans to study how its GLP-1 drugs marketed as Wegovy and Ozempic for obesity and diabetes can help tackle ...

Novo Nordisk considers exploring GLP-1 drugs like semaglutide for addiction treatment, following Eli Lilly's interest.

Pharmacy Integration with Gifthealth to Extend Seamless Support for FDA-Approved Medication to Obesity Program Members ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.